Request Demo
Last update 30 Aug 2025
Metabolically Armed CD19 CAR-T cells(Leman Biotech )
Last update 30 Aug 2025
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms META10-19 |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with Metabolically Armed CD19 CAR-T cells(Leman Biotech )NCT06711146
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
NCT06716164
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
NCT06393335
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
100 Clinical Results associated with Metabolically Armed CD19 CAR-T cells(Leman Biotech )
Login to view more data
100 Translational Medicine associated with Metabolically Armed CD19 CAR-T cells(Leman Biotech )
Login to view more data
100 Patents (Medical) associated with Metabolically Armed CD19 CAR-T cells(Leman Biotech )
Login to view more data
100 Deals associated with Metabolically Armed CD19 CAR-T cells(Leman Biotech )
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Systemic Lupus Erythematosus | Phase 1 | China | 10 Feb 2025 | |
| B-Cell Malignant Neoplasm | Phase 1 | China | 15 May 2024 | |
| Triple-Hit Lymphoma | Phase 1 | China | 15 May 2024 | |
| Diffuse large B-cell lymphoma recurrent | Phase 1 | China | 20 Nov 2023 | |
| Pre B-cell acute lymphoblastic leukemia | Phase 1 | China | 15 Feb 2023 | |
| Acute Lymphoblastic Leukemia | Phase 1 | China | 10 Feb 2023 | |
| CD19 Expressing Malignancies | Phase 1 | China | 10 Feb 2023 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | China | 10 Feb 2023 | |
| Mediastinal large B-cell lymphoma | Phase 1 | China | 10 Feb 2023 | |
| Myeloma recurrence | Phase 1 | China | 10 Feb 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 17 | sigqlznhmg(vbhjekaqij) = rbxhtpryaq pntxzesaws (cxlvocaiuf ) View more | Positive | 14 May 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free